Mutations in the serine-threonine kinase with-no-lysine 4 (WNK4) cause pseudohypoaldosteronism type 2 (PHAII), a Mendelian form of human hypertension. WNK4 regulates diverse ion transporters in the kidney, and dysregulation of renal transporters is considered the main cause of the WNK4 mutation-associated hypertension. Another determinant of hypertension is vascular tone that is regulated by Ca 2+ -dependent blood vessel constriction. However, the role of WNK4 in vasoconstriction as part of its function to regulate blood pressure is not known. Here, we report that WNK4 is a unique modulator of blood pressure by restricting Ca 2+ influx via the transient receptor potential canonical 3 (TRPC3) channel in the vasculature. Loss of WNK4 markedly augmented TRPC3-mediated Ca 2+ influx in vascular smooth muscle cells (VSMCs) in response to α-adrenoreceptor stimulation, which is the pathological hallmark of hypertension in resistance arteries. Notably, WNK4 depletion induced hypertrophic cell growth in VSMCs and increased vasoconstriction in small mesenteric arteries via TRPC3-mediated Ca 2+ influx. In addition, WNK4 mutants harboring the Q562E PHAII-causing or the D318A kinase-inactive mutation failed to mediate TRPC3 inhibition. These results define a previously undescribed function of WNK4 and reveal a unique therapeutic target to control blood pressure in WNK4-related hypertension.
Mutations in the serine-threonine kinase with-no-lysine 4 (WNK4) cause pseudohypoaldosteronism type 2 (PHAII), a Mendelian form of human hypertension. WNK4 regulates diverse ion transporters in the kidney, and dysregulation of renal transporters is considered the main cause of the WNK4 mutation-associated hypertension. Another determinant of hypertension is vascular tone that is regulated by Ca 2+ -dependent blood vessel constriction. However, the role of WNK4 in vasoconstriction as part of its function to regulate blood pressure is not known. Here, we report that WNK4 is a unique modulator of blood pressure by restricting Ca 2+ influx via the transient receptor potential canonical 3 (TRPC3) channel in the vasculature. Loss of WNK4 markedly augmented TRPC3-mediated Ca 2+ influx in vascular smooth muscle cells (VSMCs) in response to α-adrenoreceptor stimulation, which is the pathological hallmark of hypertension in resistance arteries. Notably, WNK4 depletion induced hypertrophic cell growth in VSMCs and increased vasoconstriction in small mesenteric arteries via TRPC3-mediated Ca 2+ influx. In addition, WNK4 mutants harboring the Q562E PHAII-causing or the D318A kinase-inactive mutation failed to mediate TRPC3 inhibition. These results define a previously undescribed function of WNK4 and reveal a unique therapeutic target to control blood pressure in WNK4-related hypertension.
H ypertension, or elevated arterial blood pressure, is one of the most common diseases in industrialized countries, increasing the risk of a wide spectrum of cardiovascular illnesses including stroke, congestive heart failure, and myocardial infarction (1) . More than 90% of hypertensive patients are classified as essential hypertension because of the lack of knowledge regarding the gene identity involved in blood pressure regulation (2, 3) . In the last few years, most attention has been focused on the with-no-lysine (WNK) kinases, including WNK4, that were found mutated in patients with pseudohypoaldosteronism type 2 (PHAII; Online Mendelian Inheritance in Man no. 145260), which is a rare autosomal dominant disorder featuring hypertension associated with hyperkalemia, hyperchloremia, and metabolic acidosis (4) .
Mice harboring the PHAII-causing WNK4 mutations Q562E (5) and D561A (6) reconstituted the phenotypes observed in PHAII patients. Deletion of the Na + Cl − cotransporter (NCC) reversed most of the phenotypes seen in the transgenic mice harboring the PHAII-causing WNK4 mutants (5), which indicated that aberrant regulation of NCC by the mutant WNK4 is critically involved in the pathogenesis of PHAII. This finding led to the suggestion that increased Na + in systemic fluids by the altered NCC activity is associated with elevated blood pressure (7) (8) (9) (10) . Another important aspect of hypertension is vascular tone. However, despite the diverse extrarenal tissue distribution of WNK4 (11) , the expression and function of WNK4 in the resistance artery and the role in vasoconstriction as part of its function to regulate blood pressure has not been considered before.
Recent studies have suggested that the transient receptor potential canonical (TRPC) channels, such as TRPC1, TRPC3, and TRPC6, play an important role in the pathogenesis of several cardiovascular diseases and hypertension (12) (13) (14) . TRPC channels activated by G-protein-coupled receptors (GPCRs) mediate [Ca 2+ ] i increase in vascular smooth muscle cells (VSMCs), which determine luminal diameter and contractility and thus peripheral resistance that markedly influences blood flow and pressure (12) (13) (14) . In particular, accumulating evidence suggests that TRPC3 is up-regulated in hypertensive animal models (15) , as well as in patients with hypertension (16) (17) (18) , establishing a correlation between elevated TRPC3 activity and high blood pressure. Here, we report a molecular mechanism by which WNK4 regulates TRPC3 activity to determine vascular tone and its ablation by WNK4 mutations associated with hypertension. These results not only shed light on the previously undescribed signal pathway of WNK4-related hypertension, but also provide important therapeutic strategies to correct aberrant blood pressure.
Results

WNK4 Depletion Increases TRPC3 Activity and Promotes Hypertrophic
Cell Growth in VSMCs. To determine the role of WNK4 in TRPC3-mediated Ca 2+ influx in primary cultured rat aortic VSMCs, endogenous WNK4 and TRPC3 proteins were knocked down by using specific siRNAs for each protein (Fig. 1A) Fig. 1 B and C). siRNA against TRPC3 had no effect on the expression of TRPC1 and TRPC6 (Fig. S1) 
Ca
2+ has two well established effects in the cardiovascular system. Ca 2+ mediates the acute response of vasoconstrictors (20, 21) and the long-term GPCR-mediated cell hypertrophy (22) . A prominent Ca 2+ channel associated with these vascular activities is TRPC3 (23) . To assess the role of WNK4 on the TRPC3-mediated vascular hypertrophy, VSMCs were stimulated with the α-1-adrenoreceptor agonist phenylephrine (PE) for 48 h in the absence of serum, and cell hypertrophy was analyzed by measuring cell size and stress fiber formation (Fig. 1D) . To better observe the WNK4 effect, the VSMCs were stimulated with a low dose (1 μmol/L) of PE, which caused a marginal cell size increase in control cells. Significantly, depletion of WNK4 alone was sufficient to cause 16.0 ± 3.4% and 30.8 ± 7.3% increase in cell size and stress fiber (F-actin) formation, respectively. Treatment with PE further increased the hypertrophic cell growth indices ( Fig. 1 E and F) . Most notably, the WNK4 depletion-induced hypertrophic changes were abolished by knockdown of TRPC3. Collectively, these results indicate that WNK4 negatively regulates TRPC3 activity and that the loss of WNK4 function induces a TRPC3-mediated hypertrophic cell growth in VSMCs.
WNK4 Depletion Augments TRPC3-Mediated Vasoconstriction. Next, the direct role of WNK4 and TRPC3 in vasoconstriction was examined by measuring the PE-induced vasoconstriction in isolated small mesenteric arteries. Small arteries greatly contribute to blood pressure because they are highly innervated by sympathetic nerves and react dynamically to vasoactive compounds (20) . (Fig. 2B ). Arteries were mounted in an arteriograph chamber attached to a pressure myograph, and intraluminal pressure was maintained at 40 mmHg. Inner diameter of mesenteric artery was measured by using a video-recording system. The mesenteric arteries showed dose-dependent constriction in response to PE. The 500 nmol/L PE, which is within the logarithmic phase of the dose-response curve (Fig. 2C) , was applied in subsequent experiments. A summary of multiple experiments is depicted in Fig. 2D , and individual examples of video images and inner diameter recordings are presented in Fig. 2 E-H and I-L, respectively. Compared with controls treated with scrambled siRNA, depletion of TRPC3 alone in resistance arteries induced a 47% reduction in the PE-induced vasoconstriction ( arteries (Fig. 2D) . Depletion or reduction of WNK4 activity is thus likely to elicit a steep increase in peripheral vascular resistance.
Human Mutations in WNK4 Alleviate TRPC3 Inhibition. PHAII-causing mutations in WNK4 have been linked to hypertension. Therefore, it was of interest to determine the effects of PHAIIcausing mutation WNK4 Q562E on the activation of TRPC3 by GPCRs and OAG. For these experiments, HEK 293T cells were cotransfected with the G q -coupled M 3 muscarinic receptor (M 3 R), TRPC3, and the indicated WNK4 constructs and were then stimulated with the M 3 R agonist carbachol (Fig. 3A) . WT-WNK4 strongly inhibited TRPC3-mediated Ba 2+ influx, whereas WNK4 Q562E was much less effective ( Fig. 3 A and B) . Similar results were obtained when TRPC3 was directly activated by OAG (ref. 19 ; Fig. 3 C and D) . Therefore, it is conceivable that impaired inhibition of TRPC3 in the vasculature by mutant WNK4 contributes to the high blood pressure observed in PHAII patients and to the related vascular pathology.
Mechanisms Associated with WNK4-Induced Inhibition of TRPC3. To gain insight into the molecular mechanism by which WNK4 regulates TRPC3, first we analyzed the role of WNK4 kinase activity. Fig. 4 shows that the inhibitory effects of WNK4 on TRPC3 were dependent on the kinase activity of WNK4. Inactivation of kinase activity (K i , WNK4
D318A
) significantly released the inhibition of the TRPC3-mediated Ba 2+ influx by WNK4 (Fig. 4 A and B) . More direct evidence was obtained in the whole cell current measurements. HEK 293T cells were cotransfected with M 3 R, and receptor-stimulated TRPC3-mediated current was measured. Similar to the fluorescencebased Ba 2+ influx measurements, WNK4 reduced the TRPC3-mediated cation currents activated by receptor stimulation [WNK4(WT); Fig. 4 C-E] . Notably, inactivation of WNK4 kinase activity abolished this inhibition [WNK4(K i ); Fig. 4 C-E] .
Analyses on TRPC3 surface expression reveal that WNK4-induced TRPC3 inhibition is mainly mediated by decreasing its cell surface expression. As shown in Fig. 5A , WNK4 depletion induced a 60% increase in the surface expression of native TRPC3 in VSMCs. Furthermore, expression of WT-WNK4 caused a significant reduction in the surface biotinylated fractions of TRPC3 without affecting its total protein levels in HEK 293T cells. However, the PHAII-causing WNK4 Q562E and kinase-inactive WNK4 D318A mutants failed to decrease TRPC3 surface expression (Fig. 5B) . These results imply that WNK4 may modulate TRPC3 activity by maintaining proper copy number at the cell surface via a WNK4 kinase-dependent mechanism. The TRPC6 channel, which is also activated by GPCRs, and the Fig. S2 ), in agreement with the findings that knockdown of TRPC3 is sufficient to alleviate most of the WNK4 depletion-induced pathologic responses in VSMCs (Figs. 1 and 2) .
To further explore how WNK4 regulates TRPC3, we analyzed protein-protein interaction between the two proteins. Coimmunoprecipitation experiments in HEK 293T cells and rat aorta (Fig. 6 A and B) indicate that WNK4 and TRPC3 are present in a protein complex both in vitro and in vivo. Next, we designed truncated constructs of each protein (Fig. 6C) and performed coimmunoprecipitation assays with the truncated proteins to identify the WNK4 and TRPC3 interacting domains. WNK4 strongly interacts with constructs bearing the ankyrin repeats at the N terminus of TRPC3 (Fig. 6D) , which are known to be involved in the targeting of TRPC3 to the plasma membrane (25) . TRPC3 interacts with WNK4 441-799 and WNK4 , which share the first coiled-coil domain and the acidic motif where the PHAII-causing mutations are clustered ( Fig. 6E ; constructs 2 and 4 of Myc-WNK4). However, the interaction of WNK4 441-799 with TRPC3 was insufficient to retain the inhibition of TRPC3 activity by WNK4 (Fig. 6F ), which accords with the importance of the kinase activity of WNK4 for this inhibition (Fig. 4) .
Discussion
Despite its morbid consequences as a major risk factor for diverse cardiovascular diseases, only few genes have been identified to date that impart significant effects on blood pressure (26) . Hence, regulatory pathways of renal ion transport that have been revealed by the discovery of WNK4 mutations in PHAII patients provide valuable insights into the pathogenesis of hypertension. To date, fluid retention due to the increased Na + and fluid reabsorption by the kidney through increased activity of NCC is considered as the sole mechanism for the increased blood pressure in PHAII patients harboring the WNK4 Q562E mutation (5, (27) (28) (29) . However, the expression of WNK4 in diverse extrarenal tissues (11) suggests that an additional pathway may contribute to the elevated blood pressure. In addition to blood volume ex- D318A mutant failed to inhibit TRPC3 activity. *P < 0.05 from TRPC3 + WNK4(WT). Q562E and the kinase inactive WNK4(K i ) mutants showed no significant reduction in surface TRPC3. *P < 0.05 from TRPC3 + WNK4(WT).
pansion, increased vascular resistance is a major determinant of hypertension. Accordingly, the present study provides an important reference on the expression and function of WNK4 in the vasculature and its direct role in the control of vascular resistance.
Our findings indicate that regulation of blood pressure by WNK4 is more complex than previously assumed. Notably, WNK4 is directly involved in the control of vascular tone by reducing TRPC3 activity (Fig. 2) . TRPC3 and TRPC6 mediate cation influx evoked by stimulation of GPCRs that controls vasoconstriction in the resistance artery (14, 15, 23 (Fig. S2) , which suggests that the primary effect of WNK4 on the vasculature is mediated by regulation of TRPC3 function.
Previous reports suggested that TRPC3 activity is essential for cardiovascular hypertrophy induced by angiotensin II (23) . Accordingly, TRPC3 depletion abolished α-adrenoreceptorinduced hypertrophic cell growth in VSMCs (Fig. 1 D-F) , which is likely to increase the wall thickness/lumen diameter (W/L) ratio and raise peripheral resistance. Activations of angiotensin II receptor and α-adrenoreceptor are critical signaling cascades in the progression of human hypertension and related cardiovascular diseases. Importantly, WNK4 negatively regulated TRPC3 and greatly reduced TRPC3-mediated vascular hypertrophy (Fig. 1) . Of note, histological analysis of mice harboring the Q562E (5) and D561A (6) mutations showed significant increase in the luminal surface area and size of the distal convoluted tubules (DCTs) by an unknown mechanism. In addition, increased expression of TRPV6 was recently observed in the DCTs of the WNK4 D561A/+ mouse (30) . Similar to TRPC3 in VSMCs, the aberrant regulation of Ca 2+ -permeable channels in the kidney (31) might be responsible for the hypertrophic phenotype observed in the DCTs of transgenic mice. Together, these results raise the possibility that WNK4 may be a potential therapeutic target both to acutely control blood pressure and to chronically modulate vascular remodeling.
Similar to WNK4 regulation on NCC (29, 32, 33) , WT-WNK4 inhibits TRPC3 activity by regulating its surface abundance, which was dependent on the kinase activity of WNK4. Similarly, parallel to the effect on NCC, the aberrant regulation by WNK4 Q562E increased the surface expression of TRPC3 and thus raised [Ca 2+ ] i . The combined effect of WNK4 on NCC and TRPC3 would likely function to set both adequate blood volume and peripheral resistance in normal subjects. Mutations in WNK4, such as WNK4 Q562E , or altered WNK4 activity due to mutations in WNK1 (32, 33) , would increase blood volume and induce vasoconstriction to raise blood pressure in PHAII patients. The present findings have direct clinical implications, in which a combination of vasodilators in addition to the NCC inhibitor thiazide diuretics should be considered in the treatment of WNK4-related hypertension, especially in those who exhibit limited response to thiazide. Further characterization of WNK4 and its signaling pathways in the vasculature are needed to provide insight for possible therapeutic strategies to control aberrant blood pressure.
Materials and Methods
Plasmids, Cell Culture, and siRNAs. The mammalian expressible plasmids for mWNK4 (7), hTRPC3 (34) Isolation and Culture of VSMCs and Mesenteric Artery. The rat aortic VSMCs were isolated as reported (36) . To isolate mesenteric artery, the third and fourth branch of mesenteric arteries (120-220 μm, inner diameter) were cut into 2-to 3-mm segments for subsequent analysis. Full methods are available in SI Materials and Methods.
Immunoblotting, Immunoprecipitation, Cell Surface Biotinylation, RT-PCR, and Real-Time PCR Analysis. Conventional protocols were used in these experiments. Full methods are described in SI Materials and Methods.
Cell Hypertrophy Analysis. Fluorescent images of 300-500 cells were taken from 10-15 randomly chosen fields, and relative cell size and rhodaminephalloidin fluorescence intensity of VSMCs were analyzed by using MetaMorph software (Molecular Devices). Full methods are described in SI Materials and Methods.
Reversible Permeabilization and Arterial Constriction Analysis in Mesenteric Artery. siRNAs were introduced into intact mesenteric arteries through reversible permeabilization procedure as reported (24) . The difference in diameter at resting state (α) and maximum constricted state after PE stimulation (β) was measured as percent constriction, and each group was compared by the fold increase relative to the scrambled siRNA transfected group. % constriction = (α − β)/α × 100. Full methods are described in SI Materials and Methods.
Measurements of Ba
2+ Influx and TRPC3 Current. Ba 2+ influx was measured in cultured VSMCs and HEK 293T cells by using Fura-2 (Invitrogen) as described (34) . For current recording of TRPC3, whole cell current measurement was accomplished in M 3 R-cotransfected HEK 293T cells. Full methods are described in SI Materials and Methods.
Statistical Analysis. The results of multiple experiments are presented as the means ± SEM. Statistical analysis was performed with Student's t tests or with ANOVA followed by Tukey's multiple comparison test, as appropriate. P < 0.05 was considered statistically significant.
